Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Healthy infants in their first year of life and born at or after 35 weeks 0 days GA~* Infants who are entering their first RSV season at the time of screening~Key Exclusion Criteria:~* Meets national or other local criteria to receive commercial palivizumab~* Any fever (≥ 100.4°F \[≥ 38.0°C\], regardless of route) or acute illness within 7 days prior to randomization~* Active RSV infection (a child with signs/symptoms of respiratory infection must have negative RSV testing) or known prior history of RSV infection~* Receipt of palivizumab or other RSV monoclonal antibody or any RSV vaccine, including maternal RSV vaccination

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: 1 Year
- Healthy Volunteers: t

Study Arms:
- MEDI8897 (Type: EXPERIMENTAL): Anti-RSV monoclonal antibody with an extended half-life
- Placebo (Type: PLACEBO_COMPARATOR): Commercially available 0.9% (w/v) saline

Based on this trial design, predict the completion outcome and termination type (if applicable).